More on OKLO

 Oklo Inc. (NYSE: OKLO) has emerged as a high-profile player in the nuclear energy sector, driven by its focus on small modular reactors (SMRs) and clean energy solutions. Here’s a summary of the company’s recent stock performance 

performance:

- Oklo's stock has seen dramatic volatility, rising from under $6 in September 2024 to over $28 by late November, fueled by optimism around nuclear energy and AI-driven power demands[1].

- Currently trading at $26.27, the stock has a market cap of $3.21 billion[4][5].

- The company’s valuation is speculative, with a price-to-book ratio significantly above the sector average, reflecting future potential rather than current revenue[1][2].

Recent Developments:

1. **Strategic Partnerships**: Oklo signed agreements to deploy up to 12 GW of SMR powerhouses by 2044, significantly expanding its customer pipeline[2].

2. **Regulatory and Technical Challenges**: Critics have raised concerns about regulatory hurdles, technical risks with sodium-cooled reactor designs, and financial sustainability[1].

3. **Financials**: Oklo reported a $63.3 million loss for the first nine months of 2024 but has sufficient cash reserves to fund operations for at least seven years[1][2].

### **Outlook**

- Analysts are cautiously optimistic, with a consensus “Moderate Buy” rating and a price target of $28. However, the company’s success depends on achieving regulatory approval and operational milestones for its first reactor by 2027[2][8]. 

Oklo represents both high potential and high risk, making it a speculative investment in the clean energy sector.

Sources

[1] Going Nuclear: The Story Behind Oklo's Stock Surge https://luckboxmagazine.com/trades/going-nuclear-story-behind-oklos-stock-surge/

[2] 3 Nuclear Power Stocks to Buy in 2025 for an AI Gold Rush https://www.westerngrainmarketing.com/news/story/30422290/3-nuclear-power-stocks-to-buy-in-2025-for-an-ai-gold-rush

[3] Oklo Inc. (OKLO) Stock Price, News, Quote & History - Yahoo Finance https://finance.yahoo.com/quote/OKLO/

[4] Investors - Stock Info - Oklo Inc. https://oklo.com/investors/stock-info/default.aspx

[5] OKLO Stock Price | Oklo Inc. Stock Quote (U.S.: NYSE) - MarketWatch https://www.marketwatch.com/investing/stock/oklo

[6] OKLO Stock Price and Chart — NYSE:OKLO - TradingView https://www.tradingview.com/symbols/NYSE-OKLO/

[7] Investor Relations - Oklo Inc. https://oklo.com/investors/overview/default.aspx

[8] Cathie Wood Dumps Sam Altman's Surging Nuclear Startup https://www.investors.com/news/cathie-wood-sam-altman-nuclear-stock-oklo-key-uranium-player/

[9] OKLO - Perplexity Finance https://www.perplexity.ai/app/finance/OKLO

CSP on PFE

Given MRNA ER miss today, I'm looking back at PFE for a long-term hold given a 6.5% dividend.  PFE is near its 52-week low, and currently the Apr 17 25 PUTS have an IV of 22%.

Based on historical data analysis, PFE typically maintains an implied volatility in the mid to high 20s range, with:

• Average IV around 27-28%
• Recent range of roughly 25-30%

This is relatively moderate IV for a large pharmaceutical company, reflecting PFE's status as an established blue-chip stock while accounting for some sector-specific volatility from drug trial results and regulatory decisions.

Compared to other pharmaceutical companies, this is on the lower end, as smaller biotech companies often trade with IVs of 50%+ due to their more binary outcome nature (drug success/failure).

If you're considering selling puts on PFE, this IV level suggests moderate premium income - not as high as more volatile stocks but typically enough to generate meaningful premium while having lower risk of large adverse moves.

Based on the available information, there are several potential catalyst events that may impact Pfizer's (PFE) stock price over the next 60 days:

1. Announcement of New Chief Scientific Officer: Pfizer is nearing completion of its search for a new CSO, with an announcement expected soon. This leadership change could influence investor sentiment.

2. Earnings Announcement: Pfizer has an earnings announcement scheduled for April 29, 2025. This event typically impacts stock prices as investors react to the company's financial performance and future outlook.

3. Dividend Payment: Pfizer is expected to pay a dividend of $0.430 per share on March 7, 2025. While this is a regular event, it may still affect short-term trading patterns.

4. GLP-1 Program Updates: Any news regarding Pfizer's once-daily formulation of danuglipron (oral GLP-1) could impact the stock price, as investors are closely watching developments in this area3.

It's important to note that the stock's performance may also be influenced by broader market trends, industry developments, and unforeseen events not mentioned in the search results.

Lyft

After strong ER last night I’m going long on Lyft this morning with 2026 15 calls.  Boa maintains but at 17 target.  Buyback is a good thing.

CRSP Earnings Beat

CRISPR Therapeutics (CRSP) reported impressive Q4 2024 earnings today, beating analyst estimates. The company posted earnings of -$0.44 per share, surpassing the consensus estimate of -$1.15 by $0.71. This significant beat demonstrates the company's strong financial performance and operational efficiency.

Key highlights from the earnings report include:

• Revenue of $35.7 million for Q4 2024
• R&D expenses decreased to $82.2 million from $95.1 million in Q4 2023
• Strong cash position with $1.9 billion in cash and equivalents as of December 31, 2024

The company's CASGEVY® treatment continues to gain momentum, with over 50 authorized treatment centers activated globally and more than 50 patients having cells collected across all regions by the end of 2024.CRISPR Therapeutics is poised for a catalyst-rich 2025, with several key updates expected across its pipeline, including:

• Updates on lead in vivo cardiovascular programs in the first half of 2025
• A broad update on CTX112 in oncology and autoimmune diseases in mid-2025
• Ongoing clinical trials for next-generation CAR T products CTX112™ and CTX131™
• Progress on in vivo gene editing candidates CTX310™ and CTX320™

Despite the earnings beat, CRISPR Therapeutics traded up only slightly, reaching $39.62 on Tuesday and broke 40 in after-hours trading.

Nuclear Power was My Trade of the Month

Too bad I didn’t take my own advice…. I’ll craft a post on the energy need for AI and Cryptocurrency mining, let alone the rest of us who still like power running to our homes.  These companies are a bit off from certification to run a small nuclear power plant in your local neighborhood but the big companies in AI are already funding some of them.  

On the Amazon earnings call power was a significant mention for growth.  All those data centers and the compute power needed to churn on all that data...

Oklo and the entire Nuclear Power Watchlist, but Oklo specifically doubled from when I mentioned it last month.